You are here

Home › Listings › Life Sciences › BioVaxys Technology Corp.

BioVaxys Technology Corp.

BioVaxys Technology Corp.
Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
BIOV
CSE Index: 
Currency: 

BioVaxys Technology Corp. is a British Columbia-registered biopharmaceuticals company based in Ontario, Canada that is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer. BioVaxys is also exploring vaccines for additional cancers and infectious diseases based on its HapTenix©platform through academic and other collaborations.

You are here

Home

BioVaxys Technology Corp. (BIOV)

SEDAR Information

Search form

Company Info

Address
146 Thirtieth Street
Suite 100
Etobicoke, ON M8W 3C4
Canada
Phone
646-452-7000
Email
jpassin@biovaxys.com
Website
https://biovaxys.com/
Listing date
Wednesday, November 21, 2018
Transfer Agent
Odyssey Trust Company
Email
news@biovaxys.com
Auditor
Dale Matheson Carr-Hilton Labonte LLP

Capitalization

Issued & Outstanding: 
262058498
Reserved for Issuance: 
117371153

Company Officers

James Passin, CEO
Kenneth Kovan, COO & President
Christopher Cherry, Chief Financial Officer
James Passin, Chief Executive Officer
Christopher Cherry, Chief Financial Officer
Kenneth Kovan, Chief Operating Officer and President

News Releases

05/11/2024

BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium

31/10/2024

BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems

Bulletins

16/07/2024

2024-0715 - Reinstatement - BioVaxys Technology Corp. (BIOV)

le 16 juillet/July 2024

Effective immediately, BioVaxys Technology Corp. will be reinstated for trading.

The Company has rectified the situation that gave rise to the suspension.

____________________________

Avec effet immédiat, BioVaxys Technology Corp. sera réintégrée à la négociation.

La Société a rectifié la situation qui a donné lieu à la suspension.

CSE Filings

BioVaxys Technology Corp. - CSE Form 7 - Monthly Progress Report for October 2024

BioVaxys Technology Corp. - CSE Form 9 - Notice of Issuance or Proposed Issuance of Listed Securities

BioVaxys Technology Corp. - CSE Form 6 - Certificate of Compliance

BioVaxys Technology Corp. - CSE Form 9 - Notice of Issuance or Proposed Issuance of Listed Securities

BioVaxys Technology Corp. - CSE Form 6 - Certificate of Compliance